Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States. The company's specific peptide enhanced affinity receptor T-cell platform enables it to identify cancer targets. It is involved in developing ADP-A2M10 that is in the phase I clinical trials for the treatment of non-small cell lung cancer (NSCLC), as well as urothelial, melanoma, and head and neck cancers; ADP-A2M4 that is in phase I clinical trial for solid tumor indication that include urothelial, melanoma, head and neck, ovarian, NSCLC, esophageal, gastric, synovial sarcoma, and myxoid round cell liposarcoma cancers; and ADP-A2AFP that is in phase I clinical trial for hepatocellular carcinoma. The company has a strategic collaboration and license agreement with GSK to research, develop, and commercialize NY-ESO T-cell therapy; and collaboration agreement with Noile-Immune Biotech Inc. to develop SPEAR T-cells in combination with Noile-Immune's PRIME technology. It also has a co-development and co-commercialization agreement with Universal Cells, Inc to bring new stem-cell derived allogeneic T-Cell therapies to people with cancer. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.